No­var­tis-backed Cona­tus high­lights a sil­ver lin­ing, but PhI­Ib NASH-re­lat­ed set­back caus­es whiplash in share price

The fairy tale sto­ry at Cona­tus Phar­ma­ceu­ti­cals has tak­en a nasty twist.

A lit­tle more than a year af­ter phar­ma gi­ant No­var­tis stepped in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.